Removal efficiency of micro- and nanoplastics (180 nm-125 µm) during drinking water treatment.

This study investigated the removal efficiency of micro- and nanoplastics (180 nm-125 µm) during drinking water treatment, particularly coagulation/flocculation combined with sedimentation (CFS) and granular filtration under ordinary working conditions at water treatment plants (WTPs). It also studied the interactions between biofilms and microplastics and the consequential impact on treatment efficiency. Generally, CFS was not sufficient to remove micro- and nanoplastics. The sedimentation rate of clean plastics was lower than 2.0% for all different sizes of plastic particles with coagulant Al2(SO4)3. Even with the addition of coagulant aid (PolyDADMAC), the highest removal was only 13.6% for 45-53 µm of particles. In contrast, granular filtration was much more effective at filtering out micro- and nanoplastics, from 86.9% to nearly complete removal (99.9% for particles larger than 100 µm). However, there existed a critical size (10-20 µm) where a significant lower removal (86.9%) was observed. Biofilms were easily formed on microplastics. In addition, biofilm formation significantly increased the removal efficiency of CFS treatment from <2.0% to 16.5%. This work provides new knowledge to better understand the fate and transport of emerging micro- and nanoplastic pollutants during drinking water treatment, which is of increasing concern due to the potential human exposure to micro- and nanoplastics in drinking water.

Perspectives on the recent developments with green tea polyphenols in drug discovery.

INTRODUCTION: Increasing evidence has expanded the role of green tea from a traditional beverage to a source of pharmacologically active molecules with diverse health benefits. However, conclusive clinical results are needed to better elucidate the cancer-preventive and therapeutic effects of green tea polyphenols (GTPs). Areas covered: The authors describe GTPs' chemical compositions and metabolic biotransformations, and their recent developments in drug discovery, focusing on their cancer chemopreventive and therapeutic effects. They then review the recent development of GTP-loaded nanoparticles and GTP prodrugs. Expert opinion: GTPs possess potent anticarcinogenic activities through interfering with the initiation, development and progression phases of cancer. There are several challenges (e.g. poor bioavailability) in developing GTPs as therapeutic agents. Use of nanoparticle-based delivery systems has provided unique advantages over purified GTPs. However, there is still a need to determine the actual magnitude and pharmacological mechanisms of GTPs encapsulated in nanoparticles, in order to address newly emerging safety issues associated with the potential 'local overdose' effect. The use of Pro- epigallocatechin gallate (Pro-EGCG) as a prodrug appears to offer improved in vitro stability as well as better in vivo bioavailability and efficacies in a number of animal studies, suggesting its potential as a therapeutic agent for further study and development.